Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Adv Ther (Weinh). 2021 Jan 20;4(3):2000243. doi: 10.1002/adtp.202000243

Figure 1: Platform Mechanism and SQ3370 Components.

Figure 1:

a) SQL70 biopolymer is locally injected at the tumor site, and SQP33 protodrug is infused systemically. SQP33 protodrug is captured by SQL70 biopolymer at the tumor site through a rapid covalent reaction between tetrazine (blue) and trans-cyclooctene (TCO; orange) moieties, followed by chemical rearrangement to release active Dox. b) SQL70 biopolymer is a tetrazine-modified form of sodium hyaluronate. c) SQP33 protodrug consists of doxorubicin conjugated to a reactive TCO group.